Abstract:Objective We aim to investigate the polymorphism of Cholesteryl ester transfer protein (CETP) gene –629C/A among the coronary heart disease (CHD) Han population of the Tianjin area, to evaluate the influences of genetic factors on atorvastatin therapeutic effects and clinical outcomes in pharmacogenomics and provide theoretical basis for individual treatment. Methods We studied 332 patients with angiographically confirmed CHD from October 2010 to July 2011 in the Tianjin Chest Hospital. The CETP gene promoter polymorphism at position –629 was determined by restricted fragment length polymorphism using the polymerase chain reaction (PCR-RFLP) method. Meanwhile the serum CETP levels was determined by enzyme-linked immunosorbent assay (ELISA) method. Lipid levels were determined at baseline and after 12 months of treatment with 20 mg/d atorvastatin in all patients. Clinical follow-up were performed for more than 1 year (range 12 to 23 months), major adverse cardiac events (MACE, including death, non-fatal infarction, revascularization, and stroke) were analysed. The Kaplan-Meier log-rank test was used to compare MACE-free survival between diffient genetypes. Results 1. The frequencies of variant –692A allele was 0.408, AA genotype showed reduced CETP levels and higher HDL-C levels, compared to CC, CA genotype, it did not reach statistical significance (F = 0.893, P = 0.411 and F = 1.279, P = 0.282, respectively). Although there was a negative trend correlation between serum HDL-C and CETP levels, it did not reach statistical significance (r = –0.151, P = 0.081). 2. After 12months therapy of atorvastatin, CC genotype was shown to be associated with higher LDL-C, LP (a) reduction and HDL-C elevation in reponse to atorvastatin compared with CA and AA genotype. LDL-C levels decreased 35.4% in CC homozygotes, 18.84% in CA heterozygotes and 8.15% in AA homozygotes (P = 0.001). HDL-C levels increased 14.37% in CC homozygotes, 10.48% in CA heterozygotes and 6.64% in AA homozygotes, however the changes of HDL-C levels in three genotypes showed no significant difference (P = 0.470). 3. There was a 7.83% incidience of MACE after a mean follow-up of (18.66 ± 5.99) months, 3(0.90%) cases suffered death, 7(2.11%) cases non-fatal infarction, 13(3.92%) cases revascularization and 3(0.90%) cases stroke. The cumulative MACE free survival rates were 92.4%, 85.3% and 65.0% in CC, CA and AA genotypes, respectively (Log-rank P = 0.444). Conclusions Our results suggest that variant AA genotype showed higher HDL-C levels and reduced CETP levels, however CC genotype show a better benefit of statin therapy associated with reduction in LDL-C and LP(a) levels, long-term clinical prognosis were not affected by three genotypes.

Influence of PCSK9 gene E670G polymorphism on the risk of atherosclerotic coronary heart disease and plasma lipid level

Association Between Peroxisome Proliferator-Activated Receptor-Alpha, Delta, and Gamma Polymorphisms and Risk of Coronary Heart Disease A Case-Control Study and Meta-Analysis

E670G Polymorphism Increases Risk of Coronary Artery Disease in a Chinese Han Population

ASSA13-16-1 the Influence of CETP –629C/A Polymorphism on Atorvastatin Treatment Efficacy and Clinical Outcome in Patients with Coronary Artery Disease

[Effects of Genetic Variations of Cholesteryl Ester Transfer Protein on Atorvastatin Treatment Efficacy and Clinical Outcomes in Patients with Coronary Artery Disease].

Study on association between polymorphisms in pcsk9 gene and coronary heart disease

Association of endothelial lipase gene Thr111Ile and Gly26Ser polymorphism with lipoprotein in patients with coronary heart disease

Relationships Between Genetic Polymorphisms of E670g in Pcsk9 Gene and Coronary Artery Disease: A Meta-Analysis

What is the impact of PCSK9 rs505151 and rs11591147 polymorphisms on serum lipids level and cardiovascular risk: a meta-analysis

Carriers of Three Polymorphisms of Cholesteryl Ester Transfer Protein Gene Are at Increased Risk to Coronary Heart Disease in a Chinese Population.

CETP gene polymorphisms and risk of coronary atherosclerosis in a Chinese population

The Relationship Between Polymorphism of Interleukin-1Αc-889t and Patients with Coronary Heart Disease

CYP7A1 polymorphism influences the LDL cholesterol-lowering response to atorvastatin.

A Novel CYP7A1 Polymorphism is Associated with the Low-Density Lipoprotein Cholesterol Response to Atorvastatin

[Effects of ApoE gene polymorphism on the efficacy of atorvastatin in the treatment of hyperlipidemia]

Relationship Between the Cholesterol Ester Transfer Protein TaqIB Polymorphism and the Lipid-Lowering Effect of Atorvastatin in Patients with Coronary Atherosclerotic Heart Disease.

Polymorphisms of rs2483205 and rs562556 in the PCSK9 gene are associated with coronary artery disease and cardiovascular risk factors

Association of APOA5 Polymorphisms with Plasma Lipid Levels and Severity of Coronary Stenosis in Patients with Coronary Heart Disease

[Study on the Association of Cholesteryl Ester Transfer Protein Gene Mutations with the Susceptibility to Coronary Atherosclerotic Heart Disease].

A Functional Polymorphism in the Cyp3a4 Gene is Associated with Increased Risk of Coronary Heart Disease in the Chinese Han Population

[Association Between Cholesterol 7Alpha-Hydroxylase -204A/C Gene Polymorphism and Endogenous Hypertriglyceridemia in Chinese].